Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2–10 years: A Phase II/III double-blind randomized controlled trial
- Department for International Development
- Document Type:
- Journal Article
- Kulkarni, P.S., Marchetti, E., Martellet, L., Preziosi, M.P., Viviani, S. Anand Pandit, Ashish Bavdekar, Borrow, R., Carlone, G., Elie, C., Findlow, H., Goel, A., Karupothula Suresh, LaForce, F.M., Malini Patil, Plikaytis, B., Preaud, J.M., Juvekar, S., Subhash Kapre, Suresh Beri, Suresh Jadhav, Tang YuXiao, Siddhivinayak Hirve, and Parulekar, V.
This study compares the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac™, Serum Institute of India Ltd., Pune) against the meningococcal group A component of a licensed quadrivalent meningococcal polysaccharide vaccine (PsACWY, Mencevax ACWY®, GSK, Belgium) 28 days after vaccination in Indian children. This double-blind, randomized, controlled study included 340 Indian children aged 2–10 years enrolled from August to October 2007; 169 children received a dose of PsA-TT while 171 children received a dose of PsACWY. Intention-to-treat analysis showed that 95.2% of children in PsA-TT group had a ≥4-fold response in serum bactericidal titers (rSBA) 28 days post vaccination as compared to 78.2% in the PsACWY group. A significantly higher rSBA GMT (11,209, 95%CI 9708–12,942) was noted in the PsA-TT group when compared to PsACWY group (2838, 95%CI 2368–3401). Almost all children in both vaccine groups had a ≥4-fold response in group A-specific IgG concentration but the IgG GMC was significantly greater in the PsA-TT group (89.1 μg/ml, 95%CI 75.5–105.0) when compared to the PsACWY group (15.3 μg/ml, 95%CI 12.3–19.2). Local and systemic reactions during the 4 days after immunization were similar for both vaccine groups except for tenderness (30.2% in PsA-TT group vs 12.3% in PsACWY group). None of the adverse events or serious adverse events was related to the study vaccines. We conclude that MenAfriVac™ is well tolerated and significantly more immunogenic when compared to a licensed polysaccharide vaccine, in 2- to-10-year-old Indian children.
Siddhivinayak Hirve; Ashish Bavdekar; Anand Pandit; Juvekar, S.; Malini Patil; Preziosi, M.P.; Tang YuXiao; Marchetti, E.; Martellet, L.; Findlow, H.; Elie, C.; Parulekar, V.; Plikaytis, B.; Borrow, R.; Carlone, G.; Kulkarni, P.S.; Goel, A.; Karupothula Suresh; Suresh Beri; Subhash Kapre; Suresh Jadhav; Preaud, J.M.; Viviani, S.; LaForce, F.M. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2&#8211;10 years: A Phase II/III double-blind randomized controlled trial. Vaccine (2012) 30 (45) 6456-6460. [DOI: 10.1016/j.vaccine.2012.08.004]
Document Type: Journal Article
Authors: Kulkarni, P.S. Marchetti, E. Martellet, L. Preziosi, M.P. Viviani, S. Anand Pandit Ashish Bavdekar Borrow, R. Carlone, G. Elie, C. Findlow, H. Goel, A. Karupothula Suresh LaForce, F.M. Malini Patil Plikaytis, B. Preaud, J.M. Juvekar, S. Subhash Kapre Suresh Beri Suresh Jadhav Tang YuXiao Siddhivinayak Hirve Parulekar, V.